<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medecol</journal-id><journal-title-group><journal-title xml:lang="ru">Медицина и экология</journal-title><trans-title-group xml:lang="en"><trans-title>Medicine and ecology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-6045</issn><issn pub-type="epub">2305-6053</issn><publisher><publisher-name>Карагандинский медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.59598/ME-2305-6053-2025-116-3-83-89</article-id><article-id custom-type="elpub" pub-id-type="custom">medecol-1041</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ МЕДИЦИНА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL MEDICINE</subject></subj-group></article-categories><title-group><article-title>Клинико-морфологические характеристики как предикторы развития радиойодрезистентности при раке щитовидной железы</article-title><trans-title-group xml:lang="en"><trans-title>CLINICAL AND MORPHOLOGICAL CHARACTERISTICS AS A PREDICTORS OF THE DEVELOPMENT OF RADIOIODINE RESISTANCE IN THYROID CANCER</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рахманкулова</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Rakhmankulova</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Айдана Манаровна Рахманкулова </p><p>071400, г. Семей, ул. Абая, 103</p></bio><bio xml:lang="en"><p>Aidana Manarovna Rakhmankulova </p><p>071400, Semey c., Abay str., 103</p></bio><email xlink:type="simple">dana77792@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пак</surname><given-names>Л. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Pak</surname><given-names>L. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>010000, г. Астана, ул. Керея и Жанибек хандар 3/2</p></bio><bio xml:lang="en"><p>010000, Astana c., Kerey and Zhanibek khans str., 3/2</p></bio><email xlink:type="simple">nntsot@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пивина</surname><given-names>Л. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Pivina</surname><given-names>L. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>071400, г. Семей, ул. Абая, 103</p></bio><bio xml:lang="en"><p>071400, Semey c., Abay str., 103</p></bio><email xlink:type="simple">smu@smu.edu.kz</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мусажанова</surname><given-names>Ж. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Mussazhanova</surname><given-names>Zh. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>050040, г. Алматы, пр. АльФараби, 71</p><p>Япония, г. Нагасаки 852-8523, Сакамото 1-12-4; e-mail: genkenbyori@ml.nagasaki-u.ac.jp</p></bio><bio xml:lang="en"><p>050040, Almaty c., Al-Farabi Ave., 71</p><p>Japan, Nagasaki 852-8523, Sakamoto 1-12-4</p></bio><email xlink:type="simple">info@kaznu.edu.kz</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бауржан</surname><given-names>А.</given-names></name><name name-style="western" xml:lang="en"><surname>Baurzhan</surname><given-names>A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>071400, г. Семей, улица Кутжанова 3</p></bio><bio xml:lang="en"><p>071400, Semey c., Kutzhanov st., 3</p></bio><email xlink:type="simple">mail@semeyonko.kz</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Орехов</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Orekhov</surname><given-names>А. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>071400, г. Семей, ул. Абая, 103</p></bio><bio xml:lang="en"><p>071400, Semey c., Abay str., 103</p></bio><email xlink:type="simple">smu@smu.edu.kz</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">НАО «Медицинский университет Семей»<country>Казахстан</country></aff><aff xml:lang="en">Semey Medical University NC JSC<country>Kazakhstan</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Национальный научный онкологический центр<country>Казахстан</country></aff><aff xml:lang="en">National Research Oncology Center<country>Kazakhstan</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">Казахский национальный университет им. Аль-Фараби; Отделение диагностики патологии и опухоли, Институт заболеваний от атомных взрывов, Университет Нагасаки<country>Казахстан</country></aff><aff xml:lang="en">Al-Farabi Kazakh National University; Department of Tumor And Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University<country>Kazakhstan</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru">Центр ядерной медицины и онкологии<country>Казахстан</country></aff><aff xml:lang="en">Center for Nuclear Medicine and Oncology<country>Kazakhstan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>27</day><month>09</month><year>2025</year></pub-date><volume>0</volume><issue>3</issue><fpage>83</fpage><lpage>89</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Рахманкулова А.М., Пак Л.А., Пивина Л.М., Мусажанова Ж.Б., Бауржан А., Орехов А.Ю., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Рахманкулова А.М., Пак Л.А., Пивина Л.М., Мусажанова Ж.Б., Бауржан А., Орехов А.Ю.</copyright-holder><copyright-holder xml:lang="en">Rakhmankulova A.M., Pak L.A., Pivina L.M., Mussazhanova Z.B., Baurzhan A., Orekhov А.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://medecol.qmu.kz/jour/article/view/1041">https://medecol.qmu.kz/jour/article/view/1041</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучить клинико-морфологические факторы риска развития радиойодрезистентности у пациентов с высокодифференцированным раком щитовидной железы.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Исследование проведено среди пациентов, получавших лечение в отделении радионуклидной терапии Центра ядерной медицины и онкологии УЗ области Абай. Для проведения анализа была сформирована база данных пациентов, в которую вошли 630 пациентов, прошедших лечение по поводу дифференцированного рака щитовидной железы в период с января 2021 по декабрь 2023 г. Установленным критериям включения в исследование соответствовали 373 истории болезни. Статистический анализ проводился с использованием программы SPSS 20.0.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. В ходе анализа 373 пациентов 60 были отнесены к основной группе с резистентностью к радиойодтерапии, оставшиеся 313 составили группу контроля. При оценке объема операции полная тиреоидэктомия с футлярно-фасциальным иссечением клетчатки шеи была выполнена для 58,3% пациентов основной группы, характеризующейся резистентностью к радиойодтерапии, тогда как в группе контроля этот объем вмешательства был применен только у 29,1% (р&lt;0,001). Основными гистологическими типами рака щитовидной железы в группах исследования были папиллярный рак (74,5%) и фолликулярный рак (25,5%). Наличие микрокарциномы на фоне указанных гистологических типов рака было установлено у 8 пациентов контрольной группы. Наличие отдаленных метастазов статистически значимо чаще встречалось у лиц основной группы (23,3% vs 7,3 %) в сравнении с контролем (р&lt; 0,001).</p></sec><sec><title>Выводы</title><p>Выводы. На основании проведенного анализа можно заключить, в частности выполнение тотальной тиреоидэктомии с лимфодиссекцией, статистически чаще наблюдается у пациентов с резистентностью к радиойодтерапии. Однако само по себе хирургическое лечение не является причинным фактором развития радиойодрезистентности. Вероятнее всего, расширенный объем операции отражает более агрессивное течение заболевания, которое изначально ассоциировано с риском формирования радиойодрезистентных форм опухоли. Данные гистологического исследования, выявление микрокарциномы, а также наличие отдалённых метастазов следует рассматривать в качестве клинико-морфологических факторов, ассоциированных с риском развития резистентности к радиойодтерапии у пациентов с высокодифференцированным раком щитовидной железы.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To study the clinical and morphological risk factors for the development of radioiodine resistance in patients with highly differentiated thyroid cancer.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The study was conducted among patients treated at the radionuclide therapy department of the Centre for Nuclear Medicine and Oncology of the Abay Regional Health Department. For the analysis, a database of patients who underwent radioiodine therapy was created, which included 630 patients who underwent treatment for thyroid cancer between January 2021 and December 2023. Of these, 373 medical records met the established criteria for inclusion in the study. The statistical analysis was performed using the SPSS 20.0 program.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. During the analysis of 373 patients, 60 were assigned to the main group with resistance to radioiodine therapy, and the remaining 313 were in the control group. When assessing the volume of surgery, total thyroidectomy with fascial-caseal excision of the neck tissue was performed for 58.3% of patients in the main group, characterized by resistance to radioiodine therapy, whereas in the control group, this volume of intervention was performed only in 29.1% (p&lt;0.001). The main histological types of thyroid cancer in the study groups were papillary cancer (74.5%) and follicular cancer (25.5%). The presence of microcarcinoma against the background of these histological types of cancer was found in 8 patients of the control group. The presence of distant metastases was significantly more common in the main group (23.3% vs 7.3%) compared with the control (p&lt;0.001).</p></sec><sec><title>Conclusions</title><p>Conclusions. Based on the analysis, it can be concluded that, in particular, total thyroidectomy with lymph node dissection is statistically more often observed in patients with resistance to radioiodine therapy. However, surgical treatment itself is not a causal factor in the development of radioiodine resistance. Most likely, the expanded scope of surgery reflects a more aggressive course of the disease, which is initially associated with the risk of developing radioiodine-resistant forms of tumor. Histological examination data, detection of microcarcinoma, and the presence of distant metastases should be considered as clinical and morphological factors associated with the risk of developing resistance to radioiodine therapy in patients with highly differentiated thyroid cancer.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>высокодифференцированный рак щитовидной железы</kwd><kwd>радиойодтерапия</kwd><kwd>радиойодрезистентность</kwd><kwd>факторы риска</kwd></kwd-group><kwd-group xml:lang="en"><kwd>highly differentiated thyroid cancer</kwd><kwd>radioiodine therapy</kwd><kwd>radioiodine resistance</kwd><kwd>risk factors</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Работа выполнена в рамках грантового финансирования научных и (или) научно-технических проектов на 2024 – 2026 гг. (Министерство науки и высшего образования Республики Казахстан). Грант №АP23488193 «Оптимизация системы ведения радиойодрезистентного рака щитовидной железы в Казахстане с учетом индивидуальных клинико-патологических и молекулярных характеристик».</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Global Cancer Observatory https://gco.iarc.who.int/media/globocan/factsheets/popula-tions/900-world-fact-sheet.pdf</mixed-citation><mixed-citation xml:lang="en">Global Cancer Observatory https://gco.iarc.who.int/media/globocan/factsheets/popula-tions/900-world-fact-sheet.pdf</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Показатели онкологической службы Республики Казахстан за 2022 год (статистические и аналитические материалы). Алматы; 2023: 430.</mixed-citation><mixed-citation xml:lang="en">Показатели онкологической службы Республики Казахстан за 2022 год (статистические и аналитические материалы). Алматы; 2023: 430.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Haugen B.R., Alexander E.K., Bible K.C., Doherty G.M., Mandel S.J., Nikiforov Y.E., Pacini F., Randolph G.W., Sawka A.M., Schlumberger M., Schuff K.G., Sherman S.I., Sosa J.A., Steward D.L., Tuttle R.M., Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26 (1): 1-133. https://doi.org/10.1089/thy.2015.0020</mixed-citation><mixed-citation xml:lang="en">Haugen B.R., Alexander E.K., Bible K.C., Doherty G.M., Mandel S.J., Nikiforov Y.E., Pacini F., Randolph G.W., Sawka A.M., Schlumberger M., Schuff K.G., Sherman S.I., Sosa J.A., Steward D.L., Tuttle R.M., Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26 (1): 1-133. https://doi.org/10.1089/thy.2015.0020</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Volpe F., Nappi C., Zampella E., Di Donna E., Maurea S., Cuocolo A., Klain M. Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer. Curr. Oncol. 2024; 31 (7): 3870-3884. https://doi.org/10.3390/curroncol31070286</mixed-citation><mixed-citation xml:lang="en">Volpe F., Nappi C., Zampella E., Di Donna E., Maurea S., Cuocolo A., Klain M. Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer. Curr. Oncol. 2024; 31 (7): 3870-3884. https://doi.org/10.3390/curroncol31070286</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y., Wang J., Hu X., Pan Z., Xu T., Xu J., Jiang L., Huang Pi., Zhang Y., Ge M. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy. Drug Resistance Updates. 2023; 68: 100939. https://doi.org/10.1016/j.drup.2023.100939</mixed-citation><mixed-citation xml:lang="en">Liu Y., Wang J., Hu X., Pan Z., Xu T., Xu J., Jiang L., Huang Pi., Zhang Y., Ge M. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy. Drug Resistance Updates. 2023; 68: 100939. https://doi.org/10.1016/j.drup.2023.100939</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson R.T., Linnehan J.E., Tongbram V., Keating K., Wirth L.J. Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review. Thyroid. 2013; 23 (4): 392-407. https://doi.org/10.1089/thy.2012.0520</mixed-citation><mixed-citation xml:lang="en">Anderson R.T., Linnehan J.E., Tongbram V., Keating K., Wirth L.J. Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review. Thyroid. 2013; 23 (4): 392-407. https://doi.org/10.1089/thy.2012.0520</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Schubert L., Mbekwe-Yepnang A.M., Wassermann J. Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status. J. Endocrinol. Invest. 2024; 47: 1573-1581. https://doi.org/10.1007/s40618-024-02352-</mixed-citation><mixed-citation xml:lang="en">Schubert L., Mbekwe-Yepnang A.M., Wassermann J. Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status. J. Endocrinol. Invest. 2024; 47: 1573-1581. https://doi.org/10.1007/s40618-024-02352-</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Feola T., Cozzolino A., Centello R., Pandozzi C., Tarsitano M.G., Giannetta E. Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer. J. Pers. Med. 2021; 11 (7): 674. https://doi.org/10.3390/jpm11070674</mixed-citation><mixed-citation xml:lang="en">Feola T., Cozzolino A., Centello R., Pandozzi C., Tarsitano M.G., Giannetta E. Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer. J. Pers. Med. 2021; 11 (7): 674. https://doi.org/10.3390/jpm11070674</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y., Lu X., Liu H. Current status of the prediction for radio-iodine refractory thyroid cancer: a narrative review. Front Endocrinol. (Lausanne). 2024; 15: 1433553. https://doi.org/10.3389/fendo.2024.1433553</mixed-citation><mixed-citation xml:lang="en">Wang Y., Lu X., Liu H. Current status of the prediction for radio-iodine refractory thyroid cancer: a narrative review. Front Endocrinol. (Lausanne). 2024; 15: 1433553. https://doi.org/10.3389/fendo.2024.1433553</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Mu Z., Zhang X., Sun D., Sun Y., Shi C., Ju G., Kai Z., Huang L., Chen L., Liang J., Lin Y. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer. J. Clin. Endocrinol. Metab. 2024; 109 (5): 1231-1240. https://doi.org/10.1210/clinem/dgad697</mixed-citation><mixed-citation xml:lang="en">Mu Z., Zhang X., Sun D., Sun Y., Shi C., Ju G., Kai Z., Huang L., Chen L., Liang J., Lin Y. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer. J. Clin. Endocrinol. Metab. 2024; 109 (5): 1231-1240. https://doi.org/10.1210/clinem/dgad697</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Meng C., Song J., Long W., Mu Z., Sun Y., Liang J., Lin Y. A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer. Front Endocrinol. (Lausanne). 2023; 14: 1109439. https://doi.org/10.3389/fendo.2023.1109439</mixed-citation><mixed-citation xml:lang="en">Meng C., Song J., Long W., Mu Z., Sun Y., Liang J., Lin Y. A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer. Front Endocrinol. (Lausanne). 2023; 14: 1109439. https://doi.org/10.3389/fendo.2023.1109439</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
